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Summary
. From 1st May 2013 to 30th April 2014 there were
35 episodes of Methicillin resistant Staphylococcus
aureus (MRSA) bacteraemia in established renal
failure patients on dialysis.
. This is now fairly stable year-on-year equating to a rate
of 0.15 episodes per 100 dialysis patient years, follow-
ing an initial decline in rates from 4.0 episodes per 100
dialysis patient years in 2005 when reporting began.
. Methicillin sensitive Staphylococcus aureus (MSSA)
bacteraemia rates were slightly higher this year at
2.23 per 100 dialysis patient years (compared with
1.59 episodes per 100 dialysis patient years last
year) with 526 episodes of blood stream infection
reported. In 2005, the ﬁrst year this was reported,
there were 1,114 MSSA bacteraemias in 54 centres.
. There were 247 Clostridium difﬁcile infection epi-
sodes with a rate of 1.05 per 100 dialysis patient
years, slightly higher than last year at 0.55 episodes
per 100 dialysis patient years.
. Escherichia coli infections occurred at a rate of 1.49
per 100 dialysis patient years, very similar to the rate
reported last year (1.32 episodes per 100 dialysis
patient years).
. This report has utilised a newmethodology to identify
cases, linking all established renal failure cases known
to the UK Renal Registry (UKRR) with all infections
reported to Public Health England and avoids the
need for the local microbiology team to ﬂag the
patient as a renal patient. This may have increased
the reliability of diagnosis at the UKRR level.
. In each infection for which access data were
collected, the presence of a central venous catheter
appeared to correlate with increased risk.
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Introduction
Infection remains the second leading cause of death in
patients with established renal failure (ERF) who received
renal replacement therapy (RRT). The high rates of
systemic infection reported in haemodialysis (HD)
patients are related to their impaired immune system,
the high number of invasive procedures they are exposed
to and the type of vascular access used [1]. This report
covers one year of reporting for Methicillin resistant
Staphylococcus aureus (MRSA), Methicillin sensitive
Staphylococcus aureus (MSSA), Escherichia coli (E. coli)
bloodstream infections (BSI) and Clostridium difﬁcile
infections (CDI) in adult patients with ERF who were
receiving dialysis in England.
Previous UK Renal Registry (UKRR) reports have
detailed the epidemiology of Staphylococcus aureus
bacteraemias, E. coli BSIs and CDIs in patients with ERF
receiving dialysis [2]. As well as the mandatory reporting
of MRSA BSIs, reporting of MSSA has been mandated
since January 2011 and E. coli BSIs since June 2011; CDI
reporting has been mandatory for all patients aged two
and above since 2007. CDIs are reported according to a
national testing protocol although during the timeframe
of this report there may have been some inter-hospital
variation in testing approaches [3].
The data were supplied by clinical staff and captured
using a secure web-based system, the Healthcare Associ-
ated Infection Data Capture System (HCAI-DCS).
Previous reports have conﬁrmed that whilst dialysis
patients remained at increased risk from MRSA there
has been a continued year on year decline in the number
of reported episodes of bacteraemia [2].
Methods
This report covers the period of 1st May 2013 to 30th April
2014. It should be noted that although reporting is mandatory
for these data collections (MRSA, MSSA and E. coli BSI and
CDI), completion of documentation of information relating to
renal failure is currently conducted on a voluntary basis depending
on the data entry policy within the reporting NHS acute Trust. The
methods used for the reporting of infections to Public Health
England (PHE) have been described in previous UKRR reports
(see appendix 1) [4, 5].
In last year’s report the number of alterations made by renal
centres varied considerably and the extent to which this reﬂected
differences in the accuracy of PHE data for their renal centre
was not known [2]. This year to standardise the case identiﬁcation
process and minimise the number of alterations made by centres,
for the ﬁrst time UKRR data were used to identify adult patients
with ERF who were receiving dialysis. This meant that identiﬁ-
cation was not dependent on the reporting of dialysis status by
individual NHS acute Trusts via PHE’s HCAI-DCS. A list of all
adult patients identiﬁed in the UKRR database as receiving dialysis
between 1st May 2013 and 30th April 2014 was sent to PHE for
identiﬁcation of bacteraemias and CDI associated with these
patients. Records of positive blood cultures of the identiﬁed
patients were then passed back to the UKRR. As this was the
ﬁrst year that the UKRR data was linked to PHE data for identiﬁ-
cation of infectious episodes in patients receiving dialysis the
additional validation and data capture step was again implemented
to ensure all records were accurately captured and completed. This
additional validation step involved emailing clinical or infection
control leads in the renal centre with the records reported to
PHE and requesting they complete the following actions:
1 Conﬁrm that each of the cases in the PHE ﬁle was correct, i.e.
that it related to a dialysis patient receiving treatment at their
centre at the time of the infection and
a Remove any cases that occurred in patients not on dialysis
and receiving treatment at their centre at the time of the
infection
b Add any cases that were not known to PHE but occurred
in patients on dialysis and receiving treatment at their
centre at the time of the infection
2 For all MRSA and MSSA cases, to conﬁrm details on the
dialysis modality and provide details on access in use at
the time of the infection.
PHE report positive blood cultures as opposed to infectious
episodes. For this report repeatedly positive blood cultures in the
same individual within four weeks were treated as the same episode,
beyond four weeks they were treated as new or re-infection. This
additional step was implemented by the UKRR after the centre vali-
dation process. This is slightly more conservative than the approach
taken for the Renal Indicator Dashboard, which deﬁnes separate
infections as being positive cultures more than two weeks apart.
Centre-speciﬁc rates for each infection are presented per 100
dialysis patient years. The denominator for this rate was calculated
at each centre by summing the number of days that every adult
dialysis patient contributed between the 1st May 2013 and
30th April 2014. For example, a patient who started dialysis on
the 1st April 2014 and remained on dialysis until at least the
30th April 2014 would contribute 30 days to the total. Similarly,
when calculating the modality speciﬁc rates, the number of days
that every dialysis patient spent on each modality during the
collection period was summed. Number of patient years at risk
by access type was estimated using data from the 2013 dialysis
access audit. The percentage of prevalent patients on each form
of vascular access on 31st December 2013 was multiplied by the
total number of patients on HD on 31st December 2013 to give
an estimate of the overall number of patient years at risk.
In order to adjust for variation in precision of estimated rate,
the rate of bacteraemia/CDI per 100 dialysis patient years has
been plotted against the centre size in a funnel plot. This process
has been repeated for each infection. In the case of MRSA, a com-
parative box plot to demonstrate the overall trend is also shown.
Table 12.1 lists the summary of audit measures stated in the
Renal Association clinical practice guidelines.
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Results
Validation
This was the ﬁrst year that UKRR data were used to
identify patients with ERF who were receiving dialysis
to link with PHE data and the second year that the
UKRR performed the additional validation and data
capture step in which centres were requested to add
any additional episodes which were not captured by
PHE. Table 12.2 displays the number of positive blood
cultures reported to PHE and the changes to the data
that occurred during the validation process. The majority
of episodes were rejected because the patient was not
receiving dialysis for established renal failure at the
time of the infection e.g. they were an acute dialysis
patient or a transplant patient at the time of infection.
(Acute dialysis patients will be included from January
2016.) The majority of additions were cases which were
not known to PHE. There were a number of positive
blood cultures reported to PHE which related to one
infectious episode, these were removed during the data
validation step.
There was some variation in the response from centres
to the validation process with some centres adding
additional episodes, and other centres not adding any.
However the number of alterations made by renal centres
was considerably lower than in the previous year’s report,
with 147 episodes added by centres during validation last
year compared with 17 episodes added by centres this
year [2].
Methicillin resistant Staphylococcus aureus
Thirty-ﬁve MRSA bacteraemias were recorded as
being associated with dialysis patients during the time
frame of this report, at a rate of 0.15 (95% CI 0.10–
0.21) per 100 dialysis patient years (table 12.3). This
rate was similar to the rate of 0.13 per 100 patients
reported last year. In previous years there has been a
steady reduction in the MRSA rates which this year
appears to have plateaued (ﬁgure 12.1). However, this
year for the ﬁrst time the identiﬁcation of cases did not
rely on local ﬂagging, so an actual continued reduction
in MRSA cannot be ruled out. The modality in use at
the time of infection was completed for all episodes but
statistically valid comparisons between the modalities
are difﬁcult due to small numbers.
Centre level data can be seen in table 12.4 and includes
the absolute number of episodes and rates per 100 dialysis
patient years. The majority of centres did not report any
MRSA bacteraemia episodes and only one centre had an
infection rate in excess of 1 per 100 dialysis patient years.
Figure 12.2 plots each centre’s estimated rate against the
number of patient years to take into account the greater
variation expected as centre size decreases. The extremely
Table 12.1. Summary of all audit measures stated in Renal Association (RA) clinical practice guidelines relating to infection
RA audit measure Reported Reason for non-inclusion
1 Centres should audit all Staphylococcus aureus bacteraemia (MRSA and MSSA)
episodes recorded as episodes per 100 patient years or episodes per 100 catheter
days or episodes per 100 AVF years
Yes
2 The annual Staphylococcus aureus bacteraemia rate should be less than 2.5
episodes per 100 HD patients and less than 1.0 for MRSA over two years
Yes
3 Centres should audit all episodes of Clostridium Difﬁcile toxin (CDT) and express
rates as per 100 patient years
Yes
4 Data should be collected on all episodes of VRE and ESBL bacteraemia episodes
per 100 patient years
Partly Only data on E. coli received
from PHE
ESBL = Extended-Spectrum betaLactamase; VRE = vancomycin-resistant enterococci
Table 12.2. Number of infectious episodes reported to Public
Health England (PHE) and validated by renal centres
MRSA MSSA CDI E. coli
Number of positive blood
cultures reported to PHE
37 565 242 381
Number of episodes rejected
by centres during validation
0 3 2 5
Number of episodes added by
centres during validation
2 3 11 1
Number of duplicate episodes
removed
4 39 4 25
Total number of episodes
after validation process
35 526 247 352
Epidemiology of infection in dialysis
patients
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low numbers of episodes at each centre makes the
comparison of rates uncertain.
The Renal Association (RA) audit standard states that
the annual MRSA rate should be less than 1.0 per 100 HD
patients averaged over two years. Figure 12.3 displays a
funnel plot of MRSA rate per 100 prevalent HD patients
across the two year period from 1st May 2012 to 30th
April 2014. Only one centre had a rate higher than this
standard.
Methicillin sensitive Staphylococcus aureus
In total, 526 episodes of MSSA bacteraemia were
recorded in the period covered by this report, at a rate
of 2.23 per 100 dialysis patient years (95% CI 2.05–
2.43). This was higher than last year’s rate of 1.59 per
100 dialysis patient years. One centre did not report
any MSSA episodes and the highest reported rate was
5.63 per 100 dialysis patient years (table 12.4). Based on
Table 12.3. Number and rate of infectious episodes in patients with established renal failure between 1/05/2013 and 30/04/2014, by
modality
Infection
MRSA MSSA CDI E. coli
Number of episodes
Total 35 526 247 352
HD 32 514 222 333
PD 3 12 25 19
Rate (95% CI) per 100 patient years
Total 0.15 (0.10–0.21) 2.23 (2.05–2.43) 1.05 (0.92–1.19) 1.49 (1.34–1.66)
HD 0.16 (0.11–0.22) 2.53 (2.32–2.76) 1.09 (0.96–1.25) 1.64 (1.47–1.83)
PD 0.09 (0.02–0.27) 0.37 (0.19–0.64) 0.77 (0.50–1.13) 0.58 (0.35–0.91)
HD = haemodialyis; PD = peritoneal dialysis
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Fig. 12.1. Box and whisker plot of renal centres’ MRSA rates per
100 dialysis patient years by reporting year
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Fig. 12.2. Funnel plot of the MRSA bacteraemia rate per 100
dialysis patient years by renal centre, 1stMay 2013 to 30thApril 2014
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100 prevalent HD patients, 1st May 2012 to 30th April 2014
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Table 12.4. Number and rate of infectious episodes in patients with established renal failure by renal centre
Centre
Dialysis
patient
years
Number of episodes (1/05/2013–30/04/2014) Rate per 100 dialysis patient years
MRSA MSSA CDI E. coli MRSA MSSA CDI E. coli
B Heart 467 0 13 6 11 0.00 2.79 1.29 2.36
B QEH 1,152 2 32 13 14 0.17 2.78 1.13 1.22
Basldn 191 0 5 1 2 0.00 2.62 0.52 1.05
Bradfd 231 1 13 2 5 0.43 5.63 0.87 2.17
Brightn 481 1 21 6 9 0.21 4.36 1.25 1.87
Bristol 582 0 10 7 4 0.00 1.72 1.20 0.69
Camb 479 0 11 6 13 0.00 2.29 1.25 2.71
Carlis 97 0 3 2 0 0.00 3.08 2.05 0.00
Carsh 892 4 9 7 11 0.45 1.01 0.78 1.23
Chelms 147 0 0 1 1 0.00 0.00 0.68 0.68
Colchr 116 1 3 0 1 0.86 2.59 0.00 0.86
Covnt 469 0 7 11 11 0.00 1.49 2.34 2.34
Derby 314 0 9 2 3 0.00 2.86 0.64 0.95
Donc 193 0 10 3 0 0.00 5.18 1.56 0.00
Dorset 310 0 11 3 2 0.00 3.55 0.97 0.65
Dudley 230 0 3 4 6 0.00 1.31 1.74 2.61
Exeter 482 0 5 5 10 0.00 1.04 1.04 2.07
Glouc 249 1 4 6 8 0.40 1.60 2.41 3.21
Hull 404 0 11 9 7 0.00 2.73 2.23 1.73
Ipswi 154 0 5 1 3 0.00 3.25 0.65 1.95
Kent 457 0 7 6 9 0.00 1.53 1.31 1.97
L Barts 1,142 0 30 3 19 0.00 2.63 0.26 1.66
L Guys 663 1 7 10 11 0.15 1.06 1.51 1.66
L Kings 594 0 6 2 1 0.00 1.01 0.34 0.17
L Rfree 844 1 16 4 16 0.12 1.90 0.47 1.90
L St.G 343 1 6 0 5 0.29 1.75 0.00 1.46
L West 1,515 1 25 15 18 0.07 1.65 0.99 1.19
Leeds 567 0 15 10 5 0.00 2.65 1.76 0.88
Leic 1,060 4 22 7 14 0.38 2.08 0.66 1.32
Liv Ain 182 0 4 3 2 0.00 2.20 1.65 1.10
Liv Roy 458 0 9 6 12 0.00 1.96 1.31 2.62
M RI 602 0 17 2 13 0.00 2.82 0.33 2.16
Middlbr 357 1 11 2 8 0.28 3.08 0.56 2.24
Newc 323 2 12 2 3 0.62 3.71 0.62 0.93
Norwch 371 0 3 4 6 0.00 0.81 1.08 1.62
Nottm 464 2 14 2 10 0.43 3.02 0.43 2.16
Oxford 546 1 9 10 4 0.18 1.65 1.83 0.73
Plymth 167 2 9 3 4 1.20 5.40 1.80 2.40
Ports 668 3 14 8 12 0.45 2.10 1.20 1.80
Prestn 604 0 18 11 6 0.00 2.98 1.82 0.99
Redng 361 1 8 3 6 0.28 2.22 0.83 1.66
Salford 476 2 10 6 3 0.42 2.10 1.26 0.63
Sheff 651 0 15 9 7 0.00 2.30 1.38 1.07
Shrew 220 0 8 4 5 0.00 3.64 1.82 2.28
Stevng 568 1 13 3 5 0.18 2.29 0.53 0.88
Sthend 135 0 5 0 0 0.00 3.72 0.00 0.00
Stoke 397 1 6 6 8 0.25 1.51 1.51 2.01
Sund 210 0 3 2 2 0.00 1.43 0.95 0.95
Truro 173 0 5 4 5 0.00 2.89 2.31 2.89
Wirral 240 1 6 2 4 0.42 2.50 0.83 1.67
Wolve 384 0 6 1 3 0.00 1.56 0.26 0.78
York 165 0 2 2 5 0.00 1.22 1.22 3.04
England 23,546 35 526 247 352 0.15 2.23 1.05 1.49
Epidemiology of infection in dialysis
patients
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the reported data, 46% of centres in England reported
rates of MSSA higher than the Renal Association stan-
dard. The rates have remained fairly steady over the
past three years although with a slight increasing trend
(ﬁgure 12.4). Again, caution must be exercised when
making year on year comparisons as the apparent vari-
ation in rates may be a reﬂection on the differences in
the way the data has been collected and validated over
the years, with the data validation step by centres adopted
in the past two years and UKRR data linked with PHE
data for the ﬁrst time this year. Figure 12.5 plots each
centre’s estimated rate against the number of patient
years to take into account the greater variation expected
as centre size decreases.
The peritoneal dialysis (PD) cohort had a lower rate of
MSSA bacteraemia per 100 patient years than the HD
cohort (0.37, 95% CI 0.19–0.64 compared with 2.53,
95% CI 2.32–2.76) (table 12.3).
Type of dialysis access and infection
There were major variations in the number of episodes
of both MRSA and MSSA bacteraemia according to
access type. Patients dialysing through a central venous
catheter (CVC) at the time of the infection were subject
to more episodes of bacteraemia than those with other
types of access (table 12.5). Absolute rates cannot be
calculated because vascular access has until now only
been captured at one point every 12 months, so the
time at risk on each form of access was not available.
The estimated number of patient years at risk is provided
only as an estimate of the time at risk and rates derived
from this should be treated with caution. It is based on
the distribution of access types using data on the 33
centres in England who provided prevalent access data
in the 2013 dialysis access audit return. This distribution
was then applied to the total number of patients on HD
in England on 31st December 2013 to give an overall
estimate for England.
Clostridium difﬁcile
In total, 247 episodes of CDI were recorded in the
period covered by this report, at a rate of 1.05 (95% CI
0.92–1.19) per 100 dialysis patient years. Based on the
reported data, this was higher than last year’s rate of
0.55 per 100 dialysis patient years, however this may be
a reﬂection on the change in the way the data has been
collected and validated this year. Three centres did not
report any CDI episodes and the highest reported rate
was 2.41 per 100 dialysis patient years (table 12.4).
Figure 12.6 plots each centre’s estimated rate against
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Fig. 12.4. Box and whisker plot of renal centres’ MSSA rates per
100 dialysis patient years by reporting year
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Fig. 12.5. Funnel plot of theMSSAbacteraemia rate per 100 dialysis
patient years by renal centre, 1st May 2013 to 30th April 2014
Table 12.5. Type of dialysis access in use at the time of infection
for HD patients
Number of episodes
(1/05/2013–30/04/2014)
AVF AVG CVC PD No data
Estimated number of
patient years at risk
14,492 850 4,754 3,176
MRSA 6 4 21 3 1
MSSA 183 36 250 10 47
AVF = arteriovenous ﬁstula; AVG = arteriovenous graft; CVC =
central venous catheter; PD = peritoneal dialysis
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the number of patient years to take into account the
greater variation expected as centre size decreases. Rates
were higher in the HD than the PD cohort (1.09, 95%
CI 0.96–1.25 compared with 0.77, 95% CI 0.50–1.13,
respectively) (table 12.3).
Escherichia coli
A total of 352 episodes of E. coli bacteraemia were
recorded in the period covered by this report, at a rate
of 1.49 per 100 dialysis patient years (95% CI 1.34–
1.66). This was slightly higher than last year’s rate of
1.32 per 100 dialysis patient years, however this may be
a reﬂection on the change in the way the data has been
collected and validated this year.
Centre level data are displayed in table 12.4 with con-
siderable between-centre variation in E. coli bacteraemia
rates. Three centres did not report any episodes and the
highest reported rate was 3.21 per 100 dialysis patient
years. Figure 12.7 plots each centre’s estimated rate
against the number of patient years to take into account
the greater variation expected as centre size decreases.
Here too, PD was associated with a lower rate of
infection per 100 patient years than HD (0.58, 95% CI
0.35–0.91 compared with 1.64, 95% CI 1.47–1.83,
respectively) (table 12.3).
Conclusions
This report has presented data from one year of
infections in adult ERF patients receiving dialysis and
extends the work done in previous reports from Public
Health England and the UK Renal Registry [2]. In
previous reports the numbers and rates of MRSA BSIs
in dialysis patients had fallen. However this year the
rate has remained similar to that of last year. This change
has mirrored the general improvement in MRSA rates
seen across England over the same time period. General
measures have included increased training, awareness
and screening. In addition, there are dialysis speciﬁc
factors that have led to improvement. These include
enhanced screening programmes and increased attention
to care of access. Despite the change in the reporting
mechanism this sustained improvement is welcome.
This report also presents the third full year of report-
ing of MSSA bacteraemia episodes although MSSA was
reported in the 2005 vascular access report. The rate of
MSSA bacteraemia remained signiﬁcantly higher than
for MRSA with a 15 fold increased reporting rate.
When Staphylococcal aureus infections were ﬁrst
reported in the 2004 cohort about 1/3 were due to
MRSA. This change in pattern of resistance requires
further study.
The presence of a central venous catheter remained a
signiﬁcant risk factor for MSSA bacteraemia when com-
pared to an arteriovenous ﬁstula. However, there were a
signiﬁcant number of MSSA infections in people using
an AVF. This study is limited in determining whether
an infection was a direct consequence of the access and
there are no data on outcomes. The discrepancy between
the rates of MRSA and MSSA is notable and suggests that
MSSA continues to be a signiﬁcant issue in the dialysis
population. A recent meta-analysis suggested that the
use of mupirocin is associated with a reduced risk of
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bacteraemia in a screened population but practice within
the UK may vary considerably [6]. For example, a single
centre UK study suggested that eradication can be
effective in just 36% of individuals but is associated
with a reduced risk of MSSA bacteraemia in those who
do respond [7]. Screening programmes, eradication
therapy and access care policies for both CVC and AVF
may vary between centres. Patients remained vulnerable
to MSSA and a study of practice patterns may yield useful
insights to improve care.
Data availability on CDI and E. Coli are relatively new.
The survey this year did not ask for data on access for
these episodes but may be of indirect relevance. The
report again demonstrates centre variation. The reasons
for this are not immediately clear. CDI risk may be
associated with antibiotic exposure and data on centre
antibiotic usage may be useful. E. coli bacteraemia is
also relatively frequent. Further, there is nearly a three
fold increased risk of E. Coli bacteraemia in HD com-
pared to PD patients and while this could reﬂect haemo-
dynamic stress and gut translocation in HD patients [8],
it could also simply reﬂect the fact that HD patients tend
to be frailer and that PD is contraindicated when there is
signiﬁcant bowel disease.
The introduction of the data linkage between PHE and
UKRR this year has contributed to improved data
accuracy and completeness of the data. It has minimised
the data collection burden on centres by minimising the
number of alterations required by centres during the data
validation step. Consistency of data collection, validation
and reporting in future years will enable trends to be
more clearly identiﬁed. However, there is a need to
interpret variation between centres by exploring practice
patterns and thereby improve care.
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Appendix 1
Processes for reporting of infections to Public Health
England
All cases of Methicillin Resistant Staphylococcus aur-
eus (MRSA), Methicillin Susceptible Staphylococcus
aureus (MSSA), Escherichia coli and Clostridium difﬁcile
which satisfy the criteria below are reported via the
Healthcare Associated Infection Data Capture System
(HCAI-DCS) which is a real-time, secure web enabled
system. Criteria for what constitutes an infection are as
follows:
1 MRSA bacteraemia: The following MRSA positive
blood cultures must be reported to PHE:
All cases of MRSA bacteraemia caused by S. aureus
resistant to methicillin, oxacillin, cefoxitin or ﬂu-
cloxacillin. Further details on surveillance of
MRSA bacteraemia in patients with renal disease
are available online [1].
All reported MRSA bacteraemia are subject to a
post infection review [2]. The included renal data
includes all cases regardless of whether they were
assigned to a Trust, CCG or Third party via the
PIR process.
2 MSSA bacteraemia: The following MSSA positive
blood cultures must be reported to PHE:
All cases of MSSA bacteraemia caused by S. aureus
which are not resistant to methicillin, oxacillin,
cefoxitin, or ﬂucloxacillin i.e. not subject to MRSA
reporting.
3 E. coli bacteraemia: The following E. coli positive
blood cultures must be reported to PHE:
All laboratory conﬁrmed cases of E. coli bacteraemia
4 C. difﬁcile Infection: Any of the following deﬁnes a
C. difﬁcile infection case in patients aged 2 years and
above and must be reported to PHE [3]:
a Diarrhoeal stools (Bristol Stool types 5–7) where
the specimen is C. difﬁcile toxin positive.
b Toxic megacolon or ileostomy where the speci-
men is C. difﬁcile toxin positive.
c Pseudomembranous colitis revealed by lower
gastro-intestinal endoscopy or Computed Tom-
ography.
d Colonic histopathology characteristic of C. difﬁcile
infection (with or without diarrhoea or toxin
detection) on a specimen obtained during endo-
scopy or colectomy.
e Faecal specimens collected post-mortem where
the specimen is C. difﬁcile toxin positive or
tissue specimens collected post-mortem where
pseudomembranous colitis is revealed or colonic
histopathology is characteristic of C. difﬁcile
infection.
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